Short answer
Merck & Co. (MRK) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $16.6B (up 5.1% year over year) with net income of −$1.3B.
Q2 2026 key financials · XBRL
- Revenue
- $16.6B
- +5.1% YoY · +2.0% QoQ
- Net income
- −$1.3B
- −130.2% YoY · +68.5% QoQ
- EPS (diluted)
- −$0.54
- −130.7% YoY · +68.6% QoQ
Source: XBRL data from the Merck & Co. (MRK) Q2 2026 10-Q on SEC EDGAR. USD.
Merck & Co. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $16.6B vs $15.8B, up 5% YoY
- Welireg best growth, sales $271M, up 67% YoY
- Koselugo worst growth, alliance revenue $10M, down 76% YoY
- Terns and Cidara acquisitions totaled $16.0B, including $14.7B of R&D charges
- Pricing pressure from IRA negotiations, Medicaid rebates, and Germany’s GKV-BStabG expected to reduce future sales and profits
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Merck & Co. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.